TY - JOUR
T1 - Battling regional (stage III) lung cancer
T2 - Bumpy road of a cancer survivor in the immunotherapy age
AU - Hao, Zhonglin
AU - Biddinger, Paul
AU - Schroeder, Carsten
AU - Tariq, Khurram
PY - 2016
Y1 - 2016
N2 - A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles. Despite not being eligible for a durvalumab trial because of lack of PD-L1 expression, she had a meaningful response to nivolumab. Once every 2 weeks, infusion of nivolumab resulted in rapid tumour shrinkage in multiple areas. In the next few months, she experienced a variety of side effects, some of which were potentially life-threatening. She had disease progression 9 months into treatment.
AB - A 58-year-old woman, a heavy smoker, was diagnosed with stage III squamous cell lung cancer. She was treated with concurrent chemotherapy and radiotherapy, with partial response. 2 months later, she had haemoptysis caused by brisk bleeding from the radiated right upper lobe. Fortunately, her bleed was self-limited. 4 months later, a rapidly enlarging renal mass was discovered and turned out to be metastatic from the lung primary. Second-line chemotherapy with docetaxel and ramucirumab did not have effects on the renal mass after 2 cycles. Despite not being eligible for a durvalumab trial because of lack of PD-L1 expression, she had a meaningful response to nivolumab. Once every 2 weeks, infusion of nivolumab resulted in rapid tumour shrinkage in multiple areas. In the next few months, she experienced a variety of side effects, some of which were potentially life-threatening. She had disease progression 9 months into treatment.
UR - http://www.scopus.com/inward/record.url?scp=84978862997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978862997&partnerID=8YFLogxK
U2 - 10.1136/bcr-2016-215304
DO - 10.1136/bcr-2016-215304
M3 - Article
C2 - 27389724
AN - SCOPUS:84978862997
SN - 1757-790X
VL - 2016
JO - BMJ Case Reports
JF - BMJ Case Reports
M1 - 215304
ER -